Savior Lifetec Corporation (TPEX:4167)

Market Cap	6.44B -3.4%
Revenue (ttm)	1.20B -1.3%
Net Income	537.45M +194.7%
EPS	1.71 +200.0%
Shares Out	310.44M
PE Ratio	12.13
Forward PE	n/a
Dividend	0.40 (1.94%)
Ex-Dividend Date	Jul 14, 2025

Volume	1,611,159
Average Volume	2,085,275
Open	21.20
Previous Close	20.75
Day's Range	20.95 - 21.40
52-Week Range	14.35 - 22.60
Beta	0.34
RSI	55.12
Earnings Date	May 7, 2026

About Savior Lifetec

Savior Lifetec Corporation, a specialty injectable company, develops, produces, and supplies sterile active pharmaceutical ingredients and finished dosage formulations. The company provides various carbapenem generic drugs and injections, such as paliperidone palmitate, cetrorelix and ganirelix acetate, plecanatide, prucalopride succinate, and brinzolamide. It offers imipenem and cilastatin, meropenem, and ertapenem products. The company was founded in 1993 and is headquartered in Tainan City, Taiwan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 384
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4167

Financial Performance

In 2025, Savior Lifetec's revenue was 1.20 billion, a decrease of -1.28% compared to the previous year's 1.22 billion. Earnings were 537.45 million, an increase of 194.69%.